LP-182 Pharmacokinetics, selectivity profile, and exposure-response relationship for efficacy and safety in a phase 2 study of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with systemic lupus erythematosus

Similar Items

• First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2
  by: Ian M. Catlett, et al.
  Published: (2023-01-01)
• Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis
  by: Robert Roskoski, Jr.
  Published: (2023-03-01)
• Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects
  by: Shan Jing, et al.
  Published: (2023-11-01)
• P163 Efficacy of deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, in musculoskeletal manifestations of systemic lupus erythematosus: a subanalysis of the phase 2 PAISLEY study
  by: Richard Furie, et al.
  Published: (2024-03-01)
• S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study
  by: S Banerjee, et al.
  Published: (2022-10-01)